Advances in Chimeric Antigen Receptor (CAR)-T Cell Therapies for Solid Tumors.
Authors of this article are:
Baybutt TR, Flickinger JC Jr, Caparosa EM, Snook AE.
A summary of the article is shown below:
In 2017, the United States Food and Drug Administration (FDA) approved the first two novel cellular immunotherapies using synthetic, engineered receptors known as chimeric antigen receptors (CAR), tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta), expressed by patient-derived T cells for the treatment of hematological malignancies expressing the B-cell surface antigen CD19 in both pediatric and adult patients. This approval marked a major milestone in the use of antigen-directed ‘living drugs’ for the treatment of relapsed or refractory blood cancers, and with these two approvals, there is increased impetus to expand not only the target antigens but also the tumor types that can be targeted. This state-of-the-art review will focus on the challenges, advances, and novel approaches being utilized to implement CAR-T cell immunotherapy for the treatment of solid tumors. This article is protected by copyright. All rights reserved.
Check out the article’s website on Pubmed for more information:
This article is a good source of information and a good way to become familiar with topics such as:
Adoptive cell transfer;CAR-T Cell;CD19;Cancer;Chimeric antigen receptor;Immunotherapy;Solid tumor;Tumor infiltrating lymphocyte
Categories: Science News